Illumina (NASDAQ:ILMN) Research Coverage Started at UBS Group

UBS Group assumed coverage on shares of Illumina (NASDAQ:ILMN) in a research report sent to investors on Wednesday morning, MarketBeat.com reports. The firm issued a buy rating and a $260.00 target price on the life sciences company’s stock.

Several other analysts have also issued reports on the stock. Canaccord Genuity Group boosted their price target on shares of Illumina from $190.00 to $205.00 and gave the company a “hold” rating in a research report on Monday, August 3rd. Sanford C. Bernstein reaffirmed a “market perform” rating and issued a $215.00 price objective on shares of Illumina in a report on Friday, July 31st. Evercore reiterated an “outperform” rating on shares of Illumina in a research note on Monday, July 6th. Royal Bank Of Canada lifted their price objective on shares of Illumina from $170.00 to $230.00 and gave the company an “outperform” rating in a research note on Friday, July 31st. Finally, Zacks Research downgraded Illumina from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 1st. Ten equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $199.12.

Illumina Stock Up 2.6%

ILMN stock opened at $206.45 on Wednesday. The stock has a fifty day moving average of $200.89 and a 200-day moving average of $162.18. Illumina has a fifty-two week low of $88.00 and a fifty-two week high of $231.81. The company has a market capitalization of $31.17 billion, a price-to-earnings ratio of 38.52, a PEG ratio of 2.85 and a beta of 1.46. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.40 and a current ratio of 1.80.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Thursday, July 30th. The life sciences company reported $1.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.23 by $0.08. The business had revenue of $1.16 billion for the quarter, compared to analysts’ expectations of $1.13 billion. Illumina had a return on equity of 29.84% and a net margin of 18.36%.The firm’s quarterly revenue was up 9.4% compared to the same quarter last year. During the same period in the previous year, the business posted $1.19 EPS. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. As a group, equities research analysts predict that Illumina will post 5.36 earnings per share for the current year.

Insider Activity

In other news, Director Keith Meister sold 119,501 shares of the stock in a transaction dated Friday, September 4th. The shares were sold at an average price of $218.40, for a total value of $26,099,018.40. Following the sale, the director directly owned 770,350 shares of the company’s stock, valued at approximately $168,244,440. This represents a 13.43% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, SVP Christensen Wedel sold 1,033 shares of the firm’s stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $191.52, for a total transaction of $197,840.16. Following the completion of the transaction, the senior vice president owned 14,023 shares of the company’s stock, valued at $2,685,684.96. This trade represents a 6.86% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 2,062,465 shares of company stock worth $436,589,802. Company insiders own 2.90% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Tidal Investments LLC increased its holdings in shares of Illumina by 10.3% in the second quarter. Tidal Investments LLC now owns 93,728 shares of the life sciences company’s stock worth $16,480,000 after purchasing an additional 8,726 shares during the period. MCF Advisors LLC raised its position in shares of Illumina by 172.4% in the second quarter. MCF Advisors LLC now owns 158 shares of the life sciences company’s stock worth $28,000 after buying an additional 100 shares in the last quarter. National Pension Service boosted its stake in Illumina by 246.7% during the second quarter. National Pension Service now owns 369,856 shares of the life sciences company’s stock valued at $65,032,000 after buying an additional 263,172 shares during the period. WINTON GROUP Ltd purchased a new position in Illumina during the second quarter worth about $6,041,000. Finally, NewEdge Advisors LLC grew its position in Illumina by 8.6% during the second quarter. NewEdge Advisors LLC now owns 4,740 shares of the life sciences company’s stock worth $833,000 after buying an additional 377 shares in the last quarter. 89.42% of the stock is owned by institutional investors.

About Illumina

Illumina, Inc develops and manufactures genomic analysis technologies used by researchers, healthcare providers, pharmaceutical companies and other organizations. Its offerings include next-generation DNA sequencing systems, microarray platforms, consumables, laboratory services and bioinformatics software designed to help analyze genetic variation and biological functions.

The company’s sequencing instruments include systems for a range of applications and throughput levels, such as the NovaSeq, NextSeq, MiSeq and iSeq platforms.